Novel plant-derived bioactive metabolites that regulate immune receptor levels and confer basal priming of defenses. Applied exogenously, these metabolites create more robust infection responses and may extend plant organ lifespan, offering a new approach to crop protection without genetic modification.
This solution leverages a novel class of plant-derived bioactive metabolites that regulate immune receptor levels and confer basal priming of plant defenses. By boosting receptor levels, these metabolites lower the threshold for plants to respond to damage and microbe-associated molecular patterns, creating more robust responses to infection. The same compounds may also regulate longevity, potentially improving the lifespan of plant organs.
The technology is derived from research on an enzyme essential for both basal and systemic defense responses. While a previously known enzyme product only partially explains the full range of immune effects, the research team has identified at least one novel bioactive compound produced by this enzyme that regulates immune receptors and confers immunity when applied exogenously to naive plants.
Key features:
Research approach:
The technology is currently at an early-to-mid stage of development. Key validations completed include demonstrating that a major immune receptor's level and activity are regulated by the metabolite, that plants with elevated enzyme levels exhibit increased disease resistance, and that exudates confer immunity when applied to naive plants. Future work will focus on scaling up exudate production, isolating and identifying the active molecular candidates, and developing formulations suitable for direct plant treatment to achieve protection from infection and test longevity effects. The technology is ready for collaborative development toward agricultural applications.
The University of Chicago is a private, urban research university in Illinois, known for rigorous scholarship and translational science at a scale that pairs faculty depth with agile, industry-facing programs. An integrated academic medical center enables clinical trials and real-world evaluation, while an on-campus innovation district offers incubators, prototyping spaces, and co-working for corporate collaborations. Proximity and formal affiliations with U.S. Department of Energy national laboratories provide access to user facilities, high-performance computing, and joint appointments that streamline large, multi-institution projects. Research is backed by competitive federal funding from the NIH, NSF, DOE, and other agencies, complemented by corporate sponsorships and philanthropy. A dedicated technology transfer office supports IP strategy, licensing, industry agreements, and startup formation, connecting partners to talent and facilities.